PURPOSE: Most schizophrenic patients have mild to moderate cognitive impairment in the early stages of schizophrenia. The aim was to compare the long-term effects of various antipsychotic drugs on overall cognition and on specific cognitive domains in patients with schizophrenia or related disorders. METHODS: We searched MEDLINE and EMBASE for randomized controlled trials in which oral formulations of second-generation antipsychotic drugs were compared head-to-head or against placebo or against haloperidol. Trials had to be of at least 6 months duration to be included. We used a network meta-analysis to combine direct and indirect comparisons of the cognitive effects between antipsychotics. RESULTS: Nine studies were eligible. The median trial duration was 52 weeks. Quetiapine, olanzapine and risperidone had better effects on global cognitive score than amisulpride (p < 0.05) and haloperidol (p < 0.05). When memory tasks were considered, ziprasidone had better effect than amisulpride (0.28 [0.02-0.54]) and haloperidol (0.32 [0.09-0.55]). Quetiapine was better than other drugs (p < 0.001) on attention and processing speed tasks, followed by ziprasidone (p < 0.05) and olanzapine (p < 0.05). The effects of quetiapine, risperidone and olanzapine were better than those of amisulpride (p < 0.05) on executive functions. CONCLUSIONS: Our results suggest differences between antipsychotics in their effect on the overall cognitive score in schizophrenia. Quetiapine and olanzapine had the most positive effects, followed by risperidone, ziprasidone, amisulpride and haloperidol in that order. Significant differences were also observed according to specific cognitive tasks.
PURPOSE: Most schizophrenicpatients have mild to moderate cognitive impairment in the early stages of schizophrenia. The aim was to compare the long-term effects of various antipsychotic drugs on overall cognition and on specific cognitive domains in patients with schizophrenia or related disorders. METHODS: We searched MEDLINE and EMBASE for randomized controlled trials in which oral formulations of second-generation antipsychotic drugs were compared head-to-head or against placebo or against haloperidol. Trials had to be of at least 6 months duration to be included. We used a network meta-analysis to combine direct and indirect comparisons of the cognitive effects between antipsychotics. RESULTS: Nine studies were eligible. The median trial duration was 52 weeks. Quetiapine, olanzapine and risperidone had better effects on global cognitive score than amisulpride (p < 0.05) and haloperidol (p < 0.05). When memory tasks were considered, ziprasidone had better effect than amisulpride (0.28 [0.02-0.54]) and haloperidol (0.32 [0.09-0.55]). Quetiapine was better than other drugs (p < 0.001) on attention and processing speed tasks, followed by ziprasidone (p < 0.05) and olanzapine (p < 0.05). The effects of quetiapine, risperidone and olanzapine were better than those of amisulpride (p < 0.05) on executive functions. CONCLUSIONS: Our results suggest differences between antipsychotics in their effect on the overall cognitive score in schizophrenia. Quetiapine and olanzapine had the most positive effects, followed by risperidone, ziprasidone, amisulpride and haloperidol in that order. Significant differences were also observed according to specific cognitive tasks.
Authors: Richard S E Keefe; John A Sweeney; Hongbin Gu; Robert M Hamer; Diana O Perkins; Joseph P McEvoy; Jeffrey A Lieberman Journal: Am J Psychiatry Date: 2007-07 Impact factor: 18.112
Authors: Luna Fomsgaard; Jose L Moreno; Mario de la Fuente Revenga; Tomasz Brudek; Dea Adamsen; Cristobal Rio-Alamos; Justin Saunders; Anders Bue Klein; Ignasi Oliveras; Toni Cañete; Gloria Blazquez; Adolf Tobeña; Albert Fernandez-Teruel; Javier Gonzalez-Maeso; Susana Aznar Journal: Mol Neurobiol Date: 2017-03-06 Impact factor: 5.590
Authors: Alkomiet Hasan; Birgit Guse; Joachim Cordes; Wolfgang Wölwer; Georg Winterer; Wolfgang Gaebel; Berthold Langguth; Michael Landgrebe; Peter Eichhammer; Elmar Frank; Göran Hajak; Christian Ohmann; Pablo E Verde; Marcella Rietschel; Raees Ahmed; William G Honer; Berend Malchow; Susanne Karch; Thomas Schneider-Axmann; Peter Falkai; Thomas Wobrock Journal: Schizophr Bull Date: 2015-10-03 Impact factor: 9.306
Authors: Mei Huang; Anna R Felix; Dorothy G Flood; Chaya Bhuvaneswaran; Dana Hilt; Gerhard Koenig; Herbert Y Meltzer Journal: Psychopharmacology (Berl) Date: 2014-05-09 Impact factor: 4.530
Authors: Gina C Bao; Isabel H Bleimeister; Lydia A Zimmerman; JoDy L Wellcome; Peter J Niesman; Hannah L Radabaugh; Corina O Bondi; Anthony E Kline Journal: J Neurotrauma Date: 2019-01-09 Impact factor: 5.269